Jubbonti

Denosumab, the active ingredient in Jubbonti, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It treats osteoporosis, glucocorticoid‑induced bone loss, and bone complications associated with cancer in adults at high risk of fracture.

GNH USA supplies Jubbonti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Denosumab is a monoclonal antibody that inhibits bone resorption and is indicated for several bone‑related conditions.

- Postmenopausal osteoporosis: reduces fracture risk by increasing bone density. - Osteoporosis in men at high risk of fracture: improves bone strength and lowers fracture incidence. - Bone loss associated with glucocorticoid therapy: mitigates steroid‑induced bone deterioration. - Prevention of skeletal‑related events in patients with bone metastases from solid tumours: delays progression of bone complications. - Giant cell tumor of bone: limits tumour growth and recurrence.

Denosumab may cause a range of adverse reactions, from mild injection‑site symptoms to serious systemic events.

Common Side Effects: - Injection site pain or erythema. - Low blood calcium (hypocalcemia). - Musculoskeletal pain. - Upper respiratory tract infection. - Skin rash. - Nausea.

Serious or Rare Side Effects: - Osteonecrosis of the jaw. - Atypical femur fracture. - Severe hypersensitivity reactions, including anaphylaxis. - Serious infections. - New onset or worsening of autoimmune conditions. - Unexplained severe bone pain.

Before using Denosumab, consider the following safety measures. - Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk. - Dental health: obtain a dental examination and complete any invasive procedures before starting therapy. - Renal function: monitor patients with severe kidney impairment closely. - Concomitant anti‑resorptive therapy: avoid simultaneous use with other bone‑targeting agents. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Concurrent use with other potent anti‑resorptives (e.g., bisphosphonates) may increase risk of severe hypocalcemia. - High‑dose calcium supplements without monitoring can exacerbate hypercalcemia after discontinuation.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., methotrexate) may heighten infection risk. - Hormone replacement therapy may alter calcium balance. - Anticonvulsants that affect vitamin D metabolism may require calcium/vitamin D monitoring. - Chronic corticosteroid therapy can amplify bone loss, necessitating closer observation. - Live vaccines should be avoided during treatment due to potential reduced immune response.